糖尿病性神経障害管理の市場規模、シェア、動向分析レポート：デバイス別、用途別、最終用途別、地域別、セグメント別予測、2024年～2030年

市場規模と動向

糖尿病性神経障害管理の世界市場規模は、2023年に26億2,000万米ドルと推定され、2024年から2030年にかけてCAGR 5.8%で成長すると予測されます。市場成長の主な要因としては、糖尿病有病率の増加、高齢者人口の増加、技術の進歩、研究開発活動の増加、製品承認数の増加などが挙げられます。米国疾病予防管理センター（CDC）の統計によると、米国人口の約11.6％、3,840万人の米国人が糖尿病を患っており、その半数が生涯のどこかで糖尿病性神経障害を発症すると推定されています。

糖尿病の有病率の高さが、市場成長を牽引する主な要因です。糖尿病を管理せずに放置すると、末梢神経障害を含む様々な深刻な合併症を引き起こす可能性があります。国際糖尿病連合（IDF）によると、2021年には世界で5億3,700万人の成人が糖尿病を患っており、さらにその数は2040年までに6億4,200万人に急増すると予想されています。糖尿病の有病率は世界的に増加しており、中でも低・中所得国での増加が顕著です。西太平洋、南アジア、欧州では、2021年に糖尿病を患う成人の数が最も多く、それぞれ1億6,700万人、8,800万人、5,900万人となっています。

さらに、糖尿病性神経障害を発症しやすい高齢者の増加が顕著です。糖尿病罹病期間の長期化、神経再生能力の低下、神経障害症状を悪化させる併存疾患などの要因により、高齢者人口は特に脆弱です。世界人口の高齢化に伴い、世界保健機関（WHO）は、60歳以上の高齢者の数が2030年までに6人に1人に増加し、2020年の10億人から最近では14億人に増加すると予測しています。60歳以上の世界人口は2050年までに2倍の21億人になり、80歳以上の人口は3倍の4億2,600万人になると予想されています。このような人口動態の変化により、糖尿病や末梢神経障害などの慢性疾患にかかる可能性が高くなり、高齢者の糖尿病性神経障害のリスクが高まると予想されます。

糖尿病性神経障害管理市場の成長は、電気刺激装置、神経刺激装置、神経伝導検査装置など、機能性神経障害と末梢神経障害、自律神経障害の両方の用途を提供する様々な脳画像技術の利用可能性によって牽引されると予測されます。さらに、技術の進歩や主要な応用分野での製品承認に向けて競合するメーカーが、市場を前進させる原動力となっています。2023年10月、ボストン・サイエンティフィックは脊髄刺激装置ウェーブライター・アルファ脊髄刺激装置（SCS）について、足腰に影響を及ぼす糖尿病の合併症である有痛性糖尿病性末梢神経障害（PDN）の治療薬としてFDAの承認を取得しました。この適応拡大により、ボストン・サイエンティフィック社は、成長するPDN市場において、アボット社、メドトロニック社、ネブロ社と競合することになります。

"SCSが糖尿病患者の一部をサポートするために使用されることは、世界で最も急速に成長している慢性疾患の1つにとって重要な進歩です。

この適応拡大は、患者の苦痛を和らげるためにより多くの治療選択肢を医師に提供する、強力なインターベンショナルペインソリューションのポートフォリオを提供するという当社のコミットメントのもう一つの証です。"

ボストン・サイエンティフィックのニューロモジュレーション担当プレジデント、ジム・キャシディ

政府や民間団体が神経障害の啓発と治療のために行っているいくつかの取り組みが市場成長に寄与すると期待されています。例えば、2022年5月、Averitas Pharma社が実施した米国PDPN疾患啓発キャンペーンは、有痛性糖尿病性末梢神経障害（PDPN）患者の重大なアンメット・メディカル・ニーズについての認識を高めることを目的としています。このキャンペーンでは、患者を対象としたアンケート調査、教材、メディアツアーを実施し、疾患に対する認識を高め、患者が適切な治療を受けるよう促します。

"このユニークなコンテストは、患者が糖尿病による足の神経痛をどのように表現しているかを理解することを目的としています。

患者自身の言葉を用いて症状を再定義することで、糖尿病性末梢神経障害患者とその医療従事者が、症状について共通の言葉を使って話すようになり、診断、疾病管理、潜在的な解決策をめぐる、より生産的な会話が育まれることを目標としています。"

アヴェリタスファーマ、メディカルアフェアーズ責任者、リザンドラ・マルコンデス博士

医療技術の革新は、糖尿病性神経障害の診断、モニタリング、治療を大幅に改善しました。早期発見を可能にする高度な画像診断技術から、新しいドラッグデリバリーシステムや神経調節療法に至るまで、これらの技術的飛躍的進歩は、神経障害管理の展望を再構築しています。さらに、遠隔医療や遠隔モニタリング・ソリューションと電気的神経刺激装置の統合により、特に農村部や十分なサービスを受けていない地域の患者にとって、専門的治療へのアクセスが向上しています。例えば、2022年7月、FDAは糖尿病性末梢神経障害による慢性難治性疼痛の治療用として、DyAnsys社の経皮的電気神経刺激（PENS）装置First Reliefを認可しました。この装置は、低レベルのパルス電流を連続的に流すもので、耳の後ろに装着します。今回の承認は、First Reliefを使用した患者が痛みの強さを大幅に軽減し、振動知覚、不眠、不安などの副次的評価項目も改善したという臨床研究に基づいています。この装置は、糖尿病性末梢神経障害に伴う神経障害性疼痛に悩む患者に、非薬物、非麻薬性治療の選択肢を提供します。

"FDAがFirst Reliefを認可したことで、有効性が証明されたこの装置を、糖尿病性神経障害に関連した痛みを経験している患者の治療に使用できるようになり、大変嬉しく思っています。

ファースト・リリーフは、薬や麻薬を使用しない重要な治療オプションを提供します。"

DyAnsys CEO Srini Nageshwar

糖尿病性神経障害の経済的負担の増大により、この分野へのヘルスケア支出が増加しています。政府およびヘルスケア機関は、早期介入と包括的ケアによる長期的な費用効果を認識し、この疾患を効果的に管理するためにより多くのリソースを割り当てています。AIを用いた非侵襲的診断ツールの開発は、早期発見を強化し、よりタイムリーで効果的な治療につながります。2023年10月、カリフォルニア大学サンディエゴ校（UCSD）の研究者は、糖尿病性神経障害の診断と治療の新しい組み合わせを開発するために360万米ドルの助成金を受けた。このプロジェクトは、高度な診断ツールと標的療法を統合した包括的なアプローチを構築することを目的としています。さらに、糖尿病性神経障害管理の規制状況は進化しており、新薬、デバイス、治療法の承認が増加しています。

糖尿病性神経障害管理の世界市場レポート区分

本レポートでは、世界、地域、国レベルで収益成長を予測し、2018年から2030年までの各サブセグメントにおける最新の業界動向の分析を提供しています。この調査において、Grand View Research社は世界の糖尿病性神経障害管理市場レポートをデバイス、用途、最終用途、地域に基づいてセグメント化しています：

• デバイスの展望（売上高、2018年～2030年）
• 電気刺激装置
• 神経刺激装置
• 神経伝導検査機器
• その他の機器
• 用途の展望（売上、2018年～2030年）
• 末梢神経障害
• 自律神経障害
• 近位神経障害
• 単神経炎
• 最終用途の展望（収益、USD Million、2018年～2030年）
• 病院
• 在宅ヘルスケア
• その他の最終用途
• 地域別展望（収入、2018年～2030年）
• 北米

米国。

カナダ

メキシコ

• 欧州

英国

ドイツ

フランス

イタリア

スペイン

デンマーク

スウェーデン

ノルウェー

• アジア太平洋

日本

中国

インド

オーストラリア

タイ

韓国

• ラテンアメリカ

ブラジル

アルゼンチン

• 中東＆アフリカ

南アフリカ

サウジアラビア

アラブ首長国連邦

クウェート

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 糖尿病性神経障害管理市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• 糖尿病性神経障害管理市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 糖尿病性神経障害管理市場：デバイスの推定・動向分析

• セグメントダッシュボード
• 世界の糖尿病性神経障害管理デバイス市場の変動分析
• 世界の糖尿病性神経障害管理市場規模と動向分析、デバイス別、2018年～2030年
• 電気刺激装置
• 神経刺激装置
• 神経伝導検査装置
• その他のデバイス

第5章 糖尿病性神経障害管理市場：用途の推定・動向分析

• セグメントダッシュボード
• 世界の糖尿病性神経障害管理用途市場の変動分析
• 世界の糖尿病性神経障害管理市場の規模と動向分析、用途別、2018年～2030年
• 末梢神経障害
• 自律神経障害
• 近位神経障害
• 単神経障害（局所神経障害）

第6章 糖尿病性神経障害管理市場：最終用途の推定・動向分析

• セグメントダッシュボード
• 世界の糖尿病性神経障害管理最終用途市場変動分析
• 世界の糖尿病性神経障害管理市場の規模と動向分析、最終用途別、2018年～2030年
• 病院
• 在宅ヘルスケア
• その他のエンドユーザー

第7章 糖尿病性神経障害管理市場：デバイス、用途、最終用途別の地域推定・動向分析

• 地域別市場シェア分析、2023年および2030年
• 地域市場ダッシュボード
• 世界地域市場スナップショット
• 市場規模と予測動向分析、2018年から2030年
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• 主要企業の市場シェア分析、2023年
• Company Position Analysis
• 企業分類（新興企業、イノベーター、リーダー）
• 企業プロファイル
  • Medtronic
  • NEVRO CORP.
  • NeuroMetrix, Inc.
  • Abbott
  • Boston Scientific Corporation
  • Neuralace
  • Fremslife SrlPI
  • DyAnsys Inc.
  • IMPETO MEDICAL

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviation
• Table 3 North America diabetic neuropathy management market, By country, 2018 - 2030 (USD Million)
• Table 4 North America diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
• Table 5 North America diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
• Table 6 North America diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
• Table 7 U.S diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
• Table 8 U.S diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
• Table 9 U.S diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
• Table 10 Canada diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
• Table 11 Canada diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
• Table 12 Canada diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
• Table 13 Mexico diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
• Table 14 Mexico diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
• Table 15 Mexico diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
• Table 16 Europe diabetic neuropathy management market, By country, 2018 - 2030 (USD Million)
• Table 17 Europe diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
• Table 18 Europe diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
• Table 19 Europe diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
• Table 20 UK diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
• Table 21 UK diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
• Table 22 UK diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
• Table 23 Germany diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
• Table 24 Germany diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
• Table 25 Germany diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
• Table 26 France diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
• Table 27 France diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
• Table 28 France diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
• Table 29 Italy diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
• Table 30 Italy diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
• Table 31 Italy diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
• Table 32 Denmark diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
• Table 33 Denmark diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
• Table 34 Denmark diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
• Table 35 Sweden diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
• Table 36 Sweden diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
• Table 37 Sweden diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
• Table 38 Norway diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
• Table 39 Norway diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
• Table 40 Norway diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
• Table 41 Asia Pacific diabetic neuropathy management market, By country, 2018 - 2030 (USD Million)
• Table 42 Asia Pacific diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
• Table 43 Asia Pacific diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
• Table 44 Asia Pacific diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
• Table 45 Japan diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
• Table 46 Japan diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
• Table 47 Japan diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
• Table 48 China diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
• Table 49 China diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
• Table 50 China diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
• Table 51 India diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
• Table 52 India diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
• Table 53 Australia diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
• Table 54 Australia diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
• Table 55 Australia diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
• Table 56 South Korea diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
• Table 57 South Korea diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
• Table 58 South Korea diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
• Table 59 Thailand diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
• Table 60 Thailand diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
• Table 61 Thailand diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
• Table 62 Latin America diabetic neuropathy management market, By Country, 2018 - 2030 (USD Million)
• Table 63 Latin America diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
• Table 64 Latin America diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
• Table 65 Latin America diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
• Table 66 Brazil diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
• Table 67 Brazil diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
• Table 68 Brazil diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
• Table 69 Argentina diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
• Table 70 Argentina diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
• Table 71 Argentina diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
• Table 72 Middle East & Africa diabetic neuropathy management market, By country, 2018 - 2030 (USD Million)
• Table 73 Middle East & Africa diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
• Table 74 Middle East & Africa diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
• Table 75 Middle East & Africa diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
• Table 76 South Africa diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
• Table 77 South Africa diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
• Table 78 South Africa diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
• Table 79 Saudi Arabia diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
• Table 80 Saudi Arabia diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
• Table 81 Saudi Arabia diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
• Table 82 UAE diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
• Table 83 UAE diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
• Table 84 UAE diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)
• Table 85 Kuwait diabetic neuropathy management market, By device, 2018 - 2030 (USD Million)
• Table 86 Kuwait diabetic neuropathy management market, By application, 2018 - 2030 (USD Million)
• Table 87 Kuwait diabetic neuropathy management market, By end-use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in APAC
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value - chain - based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 Diabetic neuropathy management market: market outlook
• Fig. 14 Parent market outlook
• Fig. 15 Related/ancillary market outlook
• Fig. 16 Penetration and growth prospect mapping
• Fig. 17 Industry value chain analysis
• Fig. 18 Diabetic neuropathy management market driver impact
• Fig. 19 Diabetic neuropathy management market restraint impact
• Fig. 20 Diabetic neuropathy management market: Device movement analysis
• Fig. 21 Diabetic neuropathy management market: Device outlook and key takeaways
• Fig. 22 Electrical stimulation devices market estimates and forecast, 2018 - 2030
• Fig. 23 Neuro stimulation devices market estimates and forecast, 2018 - 2030
• Fig. 24 Nerve conduction testing devices market estimates and forecast, 2018 - 2030
• Fig. 25 Other devices market estimates and forecast, 2018 - 2030
• Fig. 26 Diabetic neuropathy management market: Application movement analysis
• Fig. 27 Diabetic neuropathy management market: Application outlook and key takeaways
• Fig. 28 Peripheral neuropathy market estimates and forecast, 2018 - 2030
• Fig. 29 Autonomic neuropathy market estimates and forecast, 2018 - 2030
• Fig. 30 Proximal neuropathy market estimates and forecast, 2018 - 2030
• Fig. 31 Mononeuropathy market estimates and forecast, 2018 - 2030
• Fig. 32 Hospitals market estimates and forecast, 2018 - 2030
• Fig. 33 Home healthcare market estimates and forecast, 2018 - 2030
• Fig. 34 Other end users market estimates and forecast, 2018 - 2030
• Fig. 35 Diabetic neuropathy management market: End use movement analysis
• Fig. 36 Diabetic neuropathy management market: End use outlook and key takeaways
• Fig. 37 Hospitals market estimates and forecast, 2018 - 2030
• Fig. 38 Home healthcare market estimates and forecast, 2018 - 2030
• Fig. 39 Others end users market estimates and forecast, 2018 - 2030
• Fig. 40 Global diabetic neuropathy management market: Regional movement analysis
• Fig. 41 Global diabetic neuropathy management market: Regional outlook and key takeaways
• Fig. 42 North America
• Fig. 43 North America market estimates and forecasts, 2018 - 2030
• Fig. 44 U.S.
• Fig. 45 U.S. market estimates and forecasts, 2018 - 2030
• Fig. 46 Canada
• Fig. 47 Canada market estimates and forecasts, 2018 - 2030
• Fig. 48 Mexico
• Fig. 49 Mexico market estimates and forecasts, 2018 - 2030
• Fig. 50 Europe
• Fig. 51 Europe market estimates and forecasts, 2018 - 2030
• Fig. 52 UK
• Fig. 53 UK market estimates and forecasts, 2018 - 2030
• Fig. 54 Germany
• Fig. 55 Germany market estimates and forecasts, 2018 - 2030
• Fig. 56 France
• Fig. 57 France market estimates and forecasts, 2018 - 2030
• Fig. 58 Italy
• Fig. 59 Italy market estimates and forecasts, 2018 - 2030
• Fig. 60 Spain
• Fig. 61 Spain market estimates and forecasts, 2018 - 2030
• Fig. 62 Denmark
• Fig. 63 Denmark market estimates and forecasts, 2018 - 2030
• Fig. 64 Sweden
• Fig. 65 Sweden market estimates and forecasts, 2018 - 2030
• Fig. 66 Norway
• Fig. 67 Norway market estimates and forecasts, 2018 - 2030
• Fig. 68 Asia Pacific
• Fig. 69 Asia Pacific market estimates and forecasts, 2018 - 2030
• Fig. 70 China
• Fig. 71 China market estimates and forecasts, 2018 - 2030
• Fig. 72 Japan
• Fig. 73 Japan market estimates and forecasts, 2018 - 2030
• Fig. 74 India
• Fig. 75 India market estimates and forecasts, 2018 - 2030
• Fig. 76 Thailand
• Fig. 77 Thailand market estimates and forecasts, 2018 - 2030
• Fig. 78 South Korea
• Fig. 79 South Korea market estimates and forecasts, 2018 - 2030
• Fig. 80 Australia
• Fig. 81 Australia market estimates and forecasts, 2018 - 2030
• Fig. 82 Latin America
• Fig. 83 Latin America market estimates and forecasts, 2018 - 2030
• Fig. 84 Brazil
• Fig. 85 Brazil market estimates and forecasts, 2018 - 2030
• Fig. 86 Mexico
• Fig. 87 Mexico market estimates and forecasts, 2018 - 2030
• Fig. 88 Argentina
• Fig. 89 Argentina market estimates and forecasts, 2018 - 2030
• Fig. 90 Middle East and Africa
• Fig. 91 Middle East and Africa market estimates and forecasts, 2018 - 2030
• Fig. 92 South Africa
• Fig. 93 South Africa market estimates and forecasts, 2018 - 2030
• Fig. 94 Saudi Arabia
• Fig. 95 Saudi Arabia market estimates and forecasts, 2018 - 2030
• Fig. 96 UAE
• Fig. 97 UAE market estimates and forecasts, 2018 - 2030
• Fig. 98 Kuwait
• Fig. 99 Kuwait market estimates and forecasts, 2018 - 2030
• Fig. 100 Market share of key market players - Diabetic neuropathy management market

Market Size & Trends

The global diabetic neuropathy management market size was estimated at USD 2.62 billion in 2023 and is expected to grow at a CAGR of 5.8% from 2024 to 2030. Major factors contributing to the market growth include the growing prevalence of diabetes, the rising geriatric population, technological advancements, increased in R&D activities, and the increase in number of product approvals. According to Centers for Disease Control and Prevention (CDC) statistics, approximately 11.6% of the U.S. population, or 38.4 million Americans, live with diabetes and are estimated that half of these individuals are likely to develop diabetic neuropathy at some point during their lifetime.

High prevalence of diabetes is the major factor driving the market growth. Diabetes, when left unmanaged, can lead to a range of serious complications, including peripheral neuropathy. According to the International Diabetes Federation (IDF), 537 million adults worldwide lived with diabetes in 2021, it further states that the number is expected to surge to 642 million by 2040. The prevalence of diabetes is increasing globally, with the most significant rises observed in low- and middle-income countries. The Western Pacific, South Asia, and Europe had the highest numbers of adults living with diabetes in 2021, at 167 million, 88 million, and 59 million respectively.

Furthermore, there is a notable increase in the number of elderly individuals prone to developing diabetic neuropathy. The geriatric population is particularly vulnerable due to factors such as longer diabetes duration, decreased nerve regeneration capacity, and comorbidities that can exacerbate neuropathic symptoms. As the global population ages, the World Health Organization (WHO) predicts that the number of people aged 60 years and older will increase to 1 in 6 by 2030, rising from 1 billion in 2020 to 1.4 billion recently. The global population of people aged 60 years, and older is expected to double to 2.1 billion by 2050, with individuals aged 80 years or older set to triple to 426 million. This demographic shift is expected to lead to a higher chances of chronic conditions like diabetes and peripheral neuropathy, increasing the risk of diabetic neuropathy among seniors.

The diabetic neuropathy management market growth is anticipated to be driven by the availability of various brain imaging technologies, including electrical stimulation devices, neuro stimulation devices, nerve conduction testing devices, which offer applications for both functional and peripheral neuropathy and autonomic neuropathy. Additionally, technological advancements and manufacturers competing for product approval in key application areas drive the market forwards. In October 2023, Boston Scientific received FDA approval for its spinal cord stimulation device WaveWriter Alpha Spinal Cord Stimulator (SCS) to treat painful diabetic peripheral neuropathy (PDN), a complication of diabetes affecting the legs and feet. This expanded indication positions Boston Scientific to compete with Abbott, Medtronic and Nevro in the growing PDN market.

"The use of SCS to support a subset of the diabetes population is an important advancement for one of the fastest growing chronic conditions in the world.

This expanded indication is another testament to our commitment to delivering a robust portfolio of interventional pain solutions that provides physicians with more treatment choices to help their patients find relief."

Jim Cassidy, president of Neuromodulation at Boston Scientific.

Several initiatives undertaken by the government and private organizations for the awareness and treatment of neuropathy are expected to contribute to market growth. For instance, in May 2022, the US PDPN Disease Awareness Campaign, conducted by Averitas Pharma, aims to raise awareness about the significant unmet medical needs of patients with painful diabetic peripheral neuropathy (PDPN). This campaign involves patient-focused surveys, educational materials, and media tours to increase disease awareness and encourage patients to seek appropriate treatment.

"We launched this unique contest in the community to better understand how patients describe diabetic nerve pain of their feet in their own terms.

By redefining the symptoms using their own words, our goal is to help diabetic peripheral neuropathy patients and their health care providers start using common language to talk about their symptoms, fostering more productive conversations around diagnosis, disease management and potential solutions."

Dr. Lizandra Marcondes, Head Medical Affairs Averitas Pharma.

Innovations in medical technology have significantly improved the diagnosis, monitoring, and treatment of diabetic neuropathy. From advanced imaging techniques that allow for early detection to novel drug delivery systems and neuromodulation therapies, these technological breakthroughs are reshaping the landscape of neuropathy management. Additionally, the integration of telemedicine and remote monitoring solutions and electrical neurostimulation devices has enhanced access to specialized care, particularly for patients in rural or underserved areas. For instance, July 2022, the FDA cleared the First Relief percutaneous electrical neurostimulation (PENS) device by DyAnsys for the treatment of chronic, intractable pain from diabetic peripheral neuropathy. The device delivers continuous pulses of low-level electrical current and is placed behind the ear. The approval was based on a clinical study that showed patients treated with First Relief experienced a significant reduction in pain intensity, as well as improvements in secondary endpoints like vibration perception, insomnia, and anxiety. The device offers a non-drug, non-narcotic treatment option for patients suffering from neuropathic pain associated with diabetic peripheral neuropathy.

''We are excited to have the FDA clearance of First Relief so that this device, which has been proven effective, can now be used to treat patients who have been experiencing pain related to diabetic neuropathy.

First Relief offers a significant treatment option without drugs or narcotics."

DyAnsys CEO Srini Nageshwar.

The growing economic burden of diabetic neuropathy has led to increased healthcare spending in this area. Governments and healthcare organizations are allocating more resources to manage this condition effectively, recognizing the long-term cost benefits of early intervention and comprehensive care. The development of non-invasive diagnostic tools using AI will enhance early detection, leading to more timely and effective treatments. In October 2023, researchers at the University of California, San Diego (UCSD) have received a grant of USD3.6 million to develop a novel combination of diagnosis and treatment for diabetic neuropathy. This project aims to create a comprehensive approach that integrates advanced diagnostic tools with targeted therapies. Further the regulatory landscape for diabetic neuropathy management is evolving, with an uptick in the approval of new drugs, devices, and treatment modalities.

Global Diabetic Neuropathy Management Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global diabetic neuropathy management market report based on devices, application, end-use, and region:

• Devices Outlook (Revenue, USD Million, 2018 - 2030)
• Electrical Stimulation Devices
• Neuro Stimulation Devices
• Nerve Conduction Testing Devices
• Other Devices
• Application Outlook (Revenue, USD Million, 2018 - 2030)
• Peripheral Neuropathy
• Autonomic Neuropathy
• Proximal Neuropathy
• Mononeuropathy
• End-use Outlook (Revenue, USD Million, 2018 - 2030)
• Hospitals
• Home Healthcare
• Other End-use
• Regional Outlook (Revenue, USD Million, 2018 - 2030)
• North America

U.S.

Canada

Mexico

• Europe

UK

Germany

France

Italy

Spain

Denmark

Sweden

Norway

• Asia Pacific

Japan

China

India

Australia

Thailand

South Korea

• Latin America

Brazil

Argentina

• Middle East & Africa

South Africa

Saudi Arabia

UAE

Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Device
  • 1.2.2. Application
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Device outlook
  • 2.2.2. Application outlook
  • 2.2.3. Modality outlook
  • 2.2.4. End use outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Diabetic Neuropathy Management Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. High prevalence of diabetes and associated disorders
    • 3.2.1.2. Technological advancements
    • 3.2.1.3. Increase in R&D activities
    • 3.2.1.4. Increasing healthcare expenditure
    • 3.2.1.5. Untapped opportunities in developing economies
    • 3.2.1.6. Increase in number of product approvals
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High-cost barrier
    • 3.2.2.2. Lack of skilled professionals
    • 3.2.2.3. Stringent regulatory approvals
• 3.3. Diabetic Neuropathy Management Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Diabetic Neuropathy Management Market: Device Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Diabetic Neuropathy Management Device Market Movement Analysis
• 4.3. Global Diabetic Neuropathy Management Market Size & Trend Analysis, by Device, 2018 to 2030 (USD Million)
• 4.4. Electrical Stimulation Devices
  • 4.4.1. Electrical stimulation devices market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Neuro Stimulation Devices
  • 4.5.1. Neuro stimulation devices market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Nerve Conduction Testing Devices
  • 4.6.1. Nerve conduction testing devices market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Other Devices
  • 4.7.1. Other devices market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Diabetic Neuropathy Management Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Diabetic Neuropathy Management Application Market Movement Analysis
• 5.3. Global Diabetic Neuropathy Management Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Peripheral Neuropathy
  • 5.4.1. Peripheral neuropathy market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Autonomic Neuropathy
  • 5.5.1. Autonomic neuropathy market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Proximal Neuropathy
  • 5.6.1. Proximal neuropathy market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Mononeuropathy (focal neuropathy)
  • 5.7.1. Mononeuropathy (focal neuropathy) market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Diabetic Neuropathy Management Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Diabetic Neuropathy Management End Use Market Movement Analysis
• 6.3. Global Diabetic Neuropathy Management Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Hospitals
  • 6.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Home Healthcare
  • 6.5.1. Diagnostic imaging centers market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Other End Users
  • 6.6.1. Others end users market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Diabetic Neuropathy Management Market: Regional Estimates & Trend Analysis By Devices, Application, End Use

• 7.1. Regional Market Share Analysis, 2023 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Competitive scenario
    • 7.5.1.3. Regulatory framework
    • 7.5.1.4. Reimbursement structure
    • 7.5.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. Reimbursement structure
    • 7.5.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. Mexico
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. Reimbursement structure
    • 7.5.3.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Competitive scenario
    • 7.6.1.3. Regulatory framework
    • 7.6.1.4. Reimbursement structure
    • 7.6.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Reimbursement structure
    • 7.6.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. Reimbursement structure
    • 7.6.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Competitive scenario
    • 7.6.4.3. Regulatory framework
    • 7.6.4.4. Reimbursement structure
    • 7.6.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Competitive scenario
    • 7.6.5.3. Regulatory framework
    • 7.6.5.4. Reimbursement structure
    • 7.6.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Competitive scenario
    • 7.6.6.3. Regulatory framework
    • 7.6.6.4. Reimbursement structure
    • 7.6.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Competitive scenario
    • 7.6.7.3. Regulatory framework
    • 7.6.7.4. Reimbursement structure
    • 7.6.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Competitive scenario
    • 7.6.8.3. Regulatory framework
    • 7.6.8.4. Reimbursement structure
    • 7.6.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Competitive scenario
    • 7.7.1.3. Regulatory framework
    • 7.7.1.4. Reimbursement structure
    • 7.7.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Reimbursement structure
    • 7.7.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Reimbursement structure
    • 7.7.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Competitive scenario
    • 7.7.4.3. Regulatory framework
    • 7.7.4.4. Reimbursement structure
    • 7.7.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Competitive scenario
    • 7.7.5.3. Regulatory framework
    • 7.7.5.4. Reimbursement structure
    • 7.7.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Competitive scenario
    • 7.7.6.3. Regulatory framework
    • 7.7.6.4. Reimbursement structure
    • 7.7.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Competitive scenario
    • 7.8.1.3. Regulatory framework
    • 7.8.1.4. Reimbursement structure
    • 7.8.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.2. Argentina
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Competitive scenario
    • 7.8.2.3. Regulatory framework
    • 7.8.2.4. Reimbursement structure
    • 7.8.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Competitive scenario
    • 7.9.1.3. Regulatory framework
    • 7.9.1.4. Reimbursement structure
    • 7.9.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Competitive scenario
    • 7.9.2.3. Regulatory framework
    • 7.9.2.4. Reimbursement structure
    • 7.9.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Competitive scenario
    • 7.9.3.3. Regulatory framework
    • 7.9.3.4. Reimbursement structure
    • 7.9.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Competitive scenario
    • 7.9.4.3. Regulatory framework
    • 7.9.4.4. Reimbursement structure
    • 7.9.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Key company market share analysis, 2023
• 8.4. Company Position Analysis
• 8.5. Company Categorization (Emerging Players, Innovators and Leaders
• 8.6. Company Profiles
  • 8.6.1. Medtronic
    • 8.6.1.1. Company overview
    • 8.6.1.2. Financial performance
    • 8.6.1.3. Device benchmarking
    • 8.6.1.4. Strategic initiatives
  • 8.6.2. NEVRO CORP.
    • 8.6.2.1. Company overview
    • 8.6.2.2. Financial performance
    • 8.6.2.3. Device benchmarking
    • 8.6.2.4. Strategic initiatives
  • 8.6.3. NeuroMetrix, Inc.
    • 8.6.3.1. Company overview
    • 8.6.3.2. Financial performance
    • 8.6.3.3. Device benchmarking
    • 8.6.3.4. Strategic initiatives
  • 8.6.4. Abbott
    • 8.6.4.1. Company overview
    • 8.6.4.2. Financial performance
    • 8.6.4.3. Device benchmarking
    • 8.6.4.4. Strategic initiatives
  • 8.6.5. Boston Scientific Corporation
    • 8.6.5.1. Company overview
    • 8.6.5.2. Financial performance
    • 8.6.5.3. Device benchmarking
    • 8.6.5.4. Strategic initiatives
  • 8.6.6. Neuralace
    • 8.6.6.1. Company overview
    • 8.6.6.2. Financial performance
    • 8.6.6.3. Device benchmarking
    • 8.6.6.4. Strategic initiatives
  • 8.6.7. Fremslife S.r.l. P.I.
    • 8.6.7.1. Company overview
    • 8.6.7.2. Financial performance
    • 8.6.7.3. Device benchmarking
    • 8.6.7.4. Strategic initiatives
  • 8.6.8. DyAnsys Inc.
    • 8.6.8.1. Company overview
    • 8.6.8.2. Financial performance
    • 8.6.8.3. Device benchmarking
    • 8.6.8.4. Strategic initiatives
  • 8.6.9. IMPETO MEDICAL
    • 8.6.9.1. Company overview
    • 8.6.9.2. Financial performance
    • 8.6.9.3. Device benchmarking
    • 8.6.9.4. Strategic initiatives